PRESTO is a multicenter, double-blind, placebo-controlled study of parallel groups of PD subjects with motor fluctuations on levodopa therapy. Planned duration of the study: 6 months (26 weeks) double blind. Planned enrollment duration: 12 months. To evaluate the efficacy, tolerability, and safety of 0.5 and 1 mg of rasagiline versus placebo in subjects with levodopa-treated Parkinson’s disease (PD) and motor fluctuations.
Our thanks to Teva Pharmaceutical Industries Ltd., Netanya, ISRAEL, who has graciously agreed to share the de-identified placebo data from the PRESTO study. Therefore, any data that is specific to the study drug will not be included. See the data dictionary for data specifics.
Below find the following documents:
1. PRESTO Protocol Synopsis
2. PRESTO Schedule of Activites (SOA)
3. PRESTO Annotated CRFs (excluding BECK & MMSE due to copyright restrictions)
4. PRESTO Data Dictionaries
5. Instructions for downloading data
6. Links to publications